Open AccessRisk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score
Author(s) -
Ebenau Jarith L.,
Lee Sven J.,
Hulsman Marc,
Tesi Niccolò,
Jansen Iris E.,
Verberk Inge M.W.,
Leeuwenstijn Mardou,
Teunissen Charlotte E.,
Barkhof Frederik,
Prins Niels D.,
Scheltens Philip,
Holstege Henne,
Berckel Bart N.M.,
Flier Wiesje M.
Publication year - 2021
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1002/dad2.12229
Subject(s) - dementia , apolipoprotein e , polygenic risk score , medicine , cohort , oncology , disease , alzheimer's disease , cognitive decline , bioinformatics , psychology , genetics , gene , biology , genotype , single nucleotide polymorphism
We investigated relationships among genetic determinants of Alzheimer's disease (AD), amyloid/tau/neurodegenaration (ATN) biomarkers, and risk of dementia. Methods We studied cognitively normal individuals with subjective cognitive decline (SCD) from the Amsterdam Dementia Cohort and SCIENCe project. We examined associations between genetic variants and ATN biomarkers, and evaluated their predictive value for incident dementia. A polygenic risk score (PRS) was calculated based on 39 genetic variants. The APOE gene was not included in the PRS and was analyzed separately. Results The PRS and APOE ε4 were associated with amyloid‐positive ATN profiles, and APOE ε4 additionally with isolated increased tau (A–T+N–). A high PRS and APOE ε4 separately predicted AD dementia. Combined, a high PRS increased while a low PRS attenuated the risk associated with ε4 carriers. Discussion Genetic variants beyond APOE are clinically relevant and contribute to the pathophysiology of AD. In the future, a PRS might be used in individualized risk profiling.